Comparison · NCT01118026-e098f991
ABVD (PET-negative) vs ABVD + BEACOPP + Radiation (PET-positive): Complete Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ABVD (PET-negative) vs ABVD + BEACOPP + Radiation (PET-positive): Complete Response. Trial comparisons, record NCT01118026-e098f991. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01118026-e098f991
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.95 | 1 | wilson | |
| Risk in group 2 | 0.762 | 0.549 | 0.894 | wilson | |
| Risk difference, group 1 minus group 2 | 0.238 | 0.0971 | 0.451 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.31 | 1.03 | 1.67 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on ABVD (PET-negative) than on ABVD + BEACOPP + Radiation (PET-positive) | 4.2 | 2.22 | 10.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ABVD (PET-negative) | Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles. \> \> Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). \>~\>~\> All patients will be followed for a maximum of ten years.\>~\> ABVD: doxorubicin 25 mg/m\^2 IV\> bleomycin 10 units/m\^2 IV\> vinblastine 6 mg/m\^2 IV\> dacarbazine 375 mg/m\^2 IV | 73 | 73 | OG000 |
| Group 2 | ABVD + BEACOPP + Radiation (PET-positive) | Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles. \> \> Patients undergo a PET scan following two cycles of ABVD. If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles). \>~\> 3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).\>~\> All patients will be followed for a maximum of ten years.\>~\> ABVD: doxorubicin 25 mg/m\^2 IV\> bleomycin 10 units/m\^2 IV\> vinblastine 6 mg/m\^2 IV\> dacarbazine 375 mg/m\^2 IV\>~\> BEACOPP: bleomycin 10 units/m\^2 IV on Day 8\> etoposide 200 mg/m\^2 IV on Days 1, 2 and 3\> doxorubicin 35 mg/m\^2 IV on Day 1\> cyclophosphamide 1250 mg/m\^2 IV on Day 1\> vincristine 1.4 mg/m\^2 IV on Day 8\> procarbazine 100 mg/m\^2 orally on Days 1-7\> prednisone 40 mg/m\^2 orally on Days 1-14\>~\> radiation therapy | 16 | 21 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Complete Response
- Description
A Complete Response (CR) is defined as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. For this endpoint, the best response at any time post-baseline was analyzed
- Time frame
- Up to 8 weeks
- Population
- All eligible patients patients who were screened for PET status and were evaluated for response are included in this analysis.
Source ClinicalTrials.gov
Trial
- Title
- Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
- NCT number
- NCT01118026
- Phases
- PHASE2
- Conditions
- Lymphoma
- Interventions
- ABVD, BEACOPP, radiation therapy
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Results first posted
- 2021-12-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01118026?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01118026-e098f991